Due to the small total sample size that exists because of the lack of randomized clinical trials and the exclusion of NSCLC patients harboring uncommon EGFR mutations from previous studies, the clinical outcomes of diverse treatment modalities for EGFR-exon- 18 mutated NSCLC have not been fully elucidated. This evidence concerns the gene EGFR and non-small cell lung carcinoma.